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abstract
PURPOSE Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer
(PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist.
METHODS Between September 21, 2005, and January 13, 2015, we randomly assigned 350 men 1:1 with T1c-
4N0M0 unfavorable-risk PC to receive radiation therapy (RT) and androgen deprivation therapy (ADT) plus
docetaxel (60 mg/m2 once every 3 weeks for three cycles before RT and 20 mg/m2 once weekly during RT)
versus ADT1 RT. We evaluated the treatment effect of adding docetaxel to ADT1 RT on the primary end point
of overall survival (OS) and the incidence of RT-induced cancers and explored whether the impact of the
treatment effect on OS differed within prostate-specific antigen (PSA) subgroups (, 4,. 20 v 4-20 ng/mL) using
the interaction test for heterogeneity adjusted for age and PC prognostic factors.
RESULTS After a median follow-up of 10.2 years, 89 men died (25.43%); of these, 42 from PC (47.19%).
Although OS was not significantly increased in the docetaxel arm (the restricted mean survival time over 10 years
was 9.11 v 8.82 years; P 5 .22), significantly fewer RT-induced cancers were observed (10-year estimates:
0.61% v 4.90%; age-adjusted hazard ratio of 0.13; 95% CI, 0.02 to 0.97; P 5 .046). The treatment effect of
adding docetaxel to ADT 1 RT on OS significantly differed in men with a PSA , 4 ng/mL versus 4-20 ng/mL
(adjusted hazard ratio: 0.27 and 1.51, respectively) because of less PC-specific mortality on the docetaxel arm
(0.00% v 28.57%) among men with PSA , 4 ng/mL.
CONCLUSION Adding docetaxel to ADT1 RT did not prolong OS in men with unfavorable-risk PC, but decreased
RT-induced cancer incidence, and may prolong OS in the subgroup of men with a PSA, 4 ng/mL by reducing
PC-specific mortality.
J Clin Oncol 00. © 2021 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Docetaxel was first approved by the US Food and Drug
Administration (FDA) for use in prostate cancer (PC) in
men with metastatic (M1) castration-resistant PC after
an overall survival (OS) benefit was observed in two
randomized controlled trials (RCTs).1,2 Later, pro-
longed OS was observed in men with newly diagnosed
M1 castration-sensitive PC when docetaxel was added
to androgen deprivation therapy (ADT) in two RCTs.3,4
Subsequently, for men with unfavorable-risk non-
metastatic (M0) PC, the addition of docetaxel to radical
prostatectomy (RP)5,10 or radiation therapy (RT) and
ADT6-9 was studied in seven RCTs; six have been
reported to date5-10 with negative or inconclusive re-
sults. Specifically, an OS benefit with a nonsignificant
reduction in PC-specific mortality (PCSM) was ob-
served in only two6,10 of the six studies where. 80% of
the patients had high-grade PC.
A plausible hypothesis for the OS benefit and a non-
significant reduction in PCSM is that docetaxel re-
duced PCSM in the small subset of men with low
prostate-specific antigen (PSA)–producing, high-
grade PC that may be resistant to conventional
ADT11-16 while also reducing non-PCSM by reducing
death from RT-induced cancers. Given that docetaxel
at low doses (ie, 20 mg/m2) is a potent radio-
sensitizer,17 it is plausible that docetaxel as used in the
current RCT can sterilize cells that survive RT-induced
damage, preventing them from developing into an RT-
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recommended when managing men with unfavorable-risk
PC given inconclusive results from previous randomized
trials,5-10 unstudied benefits may exist.
To test this hypothesis in the current RCT (ClinicalTrials.gov
Identifier: NCT00116142), we evaluate the treatment effect
of adding docetaxel to ADT 1 RT in men with newly diag-
nosed M0 unfavorable-risk PC on the primary end point of
OS and the incidence of second cancers (RT-induced, all
others) and explore this effect in men with a PSA, 4 ng/mL.
METHODS
Study Design and Oversight
This was an investigator-initiated multicenter phase III RCT
conducted in both academic and community-based health
centers in the United States, Australia, and New Zealand
(Protocol, online only). The institutional review board at
each participating institution approved the trial that was
conducted in compliance with the principles of the Dec-
laration of Helsinki and in accordance with the International
Conference on Harmonisation Guideline for Good Clinical
Practice.18 Written informed consent was obtained, and an
independent data safety and monitoring board reviewed
unblinded safety data throughout the trial. The results of the
interim analyses are shown in Appendix 1 (online only).
Patients
Eligible patients included those with histologically proven
adenocarcinoma of the prostate scored using the Gleason
scoring system by an expert genitourinary pathologist
(A.A.R.). They were required to have one or more of the
following: Clinical Tumor (T) category T2c-T4 as per the
2002 American Joint Commission on Cancer staging or
Clinical T1b-T2b and PSA level . 10 ng/mL or a biopsy
Gleason score of 4 1 3 or higher or tertiary grade 5 PC or
biopsy Gleason score 3 1 4 PC and at least 50% of the
biopsy cores positive or a PSA velocity . 2 ng/mL/year or
biopsy or radiographic evidence of seminal vesicle invasion.
There must also be no prior pelvic RT or RP; however, ADT
within 4 weeks before random assignment was permitted.
A radionuclide bone scan and computed tomography or
magnetic resonance imaging assessment of the pelvic lymph
nodes were performed to rule out the presence of bone and/
or pelvic lymph node metastasis, respectively. Up to 1.5 cm
(long axis) pelvic lymph nodes were permitted. Additional
eligibility requirements can be found in Appendix 1
Random Assignment and Interventions
As shown in the CONSORT diagram in Figure 1, patients
were randomly assigned 1:1 to 6months of ADT1RT versus
6 months of ADT 1 RT 1 10 cycles of docetaxel (three
cycles at 60 mg/m2 once every 3 weeks before RT and then
once weekly for seven cycles during RT at 20 mg/m2). The
daily RT dose was 1.8 Gy for 39 treatments to the prostate
and seminal vesicles totaling 73.7 Gy (70.2 Gy normalized to
95%) delivered using 3-dimensional conformal RT tech-
nique or intensity-modulated RT. Pelvic lymph nodes could
be treated at the discretion of the treating physician. ADT
consisted of a luteinizing hormone releasing hormone ag-
onist and antiandrogen that started 2 months before RT,
continued during RT, and concluded 2 months after RT
completion in both treatment arms. Before random as-
signment, patients were stratified by centrally reviewing a
biopsy Gleason score# 7 versus. 7 and a PSA level # 20
versus . 20 ng/mL. Treatments were assigned using per-
muted blocks created by the biostatistician (W.X.) within
strata with dynamic balancing within institutions, and pa-
tients were enrolled by the study team (M.L. and E.M.).
Assessments
Patient demographics, medical history including comor-
bidities scored using the Adult Comorbidity Evaluation-27
CONTEXT
Key Objective
We investigated whether previous randomized controlled trials missed the benefit of adding intravenous docetaxel to
radiation therapy (RT) and androgen deprivation therapy (ADT) in the management of nonmetastatic, unfavorable-risk
prostate cancer (PC).
Knowledge Generated
Amongmen randomly assigned to receive ADT 1 RT 1 docetaxel versus ADT 1 RT, significantly less RT-induced cancers
were observed. The treatment effect of adding docetaxel to ADT 1 RT on overall survival in men with a prostate-specific
antigen (PSA) , 4 ng/mL was driven by the absence of PC death, providing evidence to support a distinct biology in low
PSA-producing, unfavorable-risk PC that is docetaxel-sensitive.
Relevance
Future study is needed to assess whether oral docetaxel, given its favorable toxicity profile, can reduce RT-induced cancer
incidence, like intravenous docetaxel, across a wide variety of cancers. The absence of PC death that we observed among
men with a PSA , 4 ng/mL randomly assigned to receive docetaxel could be explored further in a meta-analysis of
previous randomized controlled trials.
2 © 2021 by American Society of Clinical Oncology
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metric,19 PC indices, and clinical T-category as per the
digital rectal examination were assessed and recorded
within 30 days before random assignment. Following the
end of RT, patients were seen for follow-up every 6 months
for 5 years and annually thereafter. At each follow-up,
serum PSA and testosterone levels were obtained. If a
patient experienced PSA failure defined as PSA
nadir 1 2 ng/mL, restaging with a bone scan and pelvic
magnetic resonance imaging or computed tomography was
performed. Collection of data at each follow-up visit on
second cancer incidence including date of diagnosis, lo-
cation, and histology was performed in addition to PSA
failure, metastatic disease, and survival status permitting
the assessment of second cancer incidence, PSA failure,
metastatic, and OS status. Adverse event occurrence,
severity, and whether they were treatment-related were
recorded as per the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0. We
also considered second cancers as part of the safety
assessment and recorded their occurrence and whether
they were treatment-related separate from the adverse
events that are included in National Cancer Institute
Common Terminology Criteria.
Clinical Outcome Measures
The primary end point was OS defined from the date of
random assignment to death from any cause with surviving
patients censored at date of last follow-up. The cause of
death was centrally reviewed by the principal investigator
(A.V.D.) who was blinded to the randomized treatment arm.
Second cancer incidence was defined from the date of
random assignment to diagnosis of a new malignancy. An
RT-induced cancer was defined as occurring within or
juxtaposed to the radiation planning target volume.20 Given
the clinical significance of an RT-induced cancer, we
evaluate the composite end point of OS or the occurrence of
an RT-induced cancer in surviving patients. Secondary end
points including PCSM, metastasis-free survival (MFS), and
Randomly assigned (N = 350)
Allocated to ADT + RT (n = 175) Allocated to ADT + RT + docetaxel (n = 175) 
Follow-up for survival
  Death                                          (n = 45)
  Actively followed                     (n = 114)
  Withdrew consent or follow-up (n = 6)
Follow-up for survival
  Death                                          (n = 44)
  Actively followed                     (n = 112)
  Withdrew consent or follow-up (n = 4)
   Received treatment                  
Received ADT only 
Did not receive treatment
Patient withdrew 
(n = 174)
(n = 171)Received ADT + RT
(n = 3)
(n = 1)
Received treatment (n = 171)
Received ADT + RT + docetaxel (n = 167)
Received ADT + docetaxel (n = 3)
Received docetaxel only (n = 1)





Diagnosis of colon cancer



















Patient refused RT and















Could not tolerate docetaxel
Depression
Physician decision
Because of bilateral ruptured tendons
Noncompliance
FIG 1. CONSORT diagram: random assignment, treatment, and follow-up. ADT, androgen depri-
vation therapy; RT, radiation therapy.
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PSA recurrence-free survival (PSA RFS) are described in
Appendix 1.
Statistical Methods
Statistical design. The study was designed to detect a
hazard ratio of 0.48, corresponding to an improved 5-year
OS from 84% (ADT1 RT) to 92% (ADT1 RT1 docetaxel)
under the exponential distribution. Initially, a one-sided
significance level of 0.05 and 80% power, which re-
quired at least 53 deaths and a target accrual of 350
patients for the final analysis using a log-rank test, were
used. However, a protocol amendment was made in
February 2018, which increased the event number to 86
deaths for the same hypothesized improvement in OS
under the one-sided alpha of .025 and 90% power given
that the statistical concerns raised over a similar previous
randomized trial6 that used a one-sided alpha of .05 and
90% power when first reported at the 2015 ASCO meeting
(Chicago, IL). The target accrual needed to make this
assessment remained unchanged at 350 patients.
Statistical Analysis
Prespecified end points. Intent-to-treat population was
used for the primary and secondary efficacy analysis.
Distribution of OS, MFS, and PSA RFS was estimated using
the Kaplan-Meier methodology.21 Cox proportional hazards
models22 estimated the treatment effect of adding doce-
taxel to ADT1 RT (hazard ratios [HRs] and 95% CI) for OS,
MFS, and PSA RFS, and the stratified log-rank test20 was
reported as the primary comparison. The proportional
hazards assumption was visually checked and tested; re-
stricted mean survival time (RMST) was provided if non-
proportionality was evident. The RMST measures the
average survival from time-zero to a specified time-point
and may be estimated as the area under the survival curve
up to that point. Cumulative incidence estimates of PCSM,
RT-induced, and all other second cancers were calculated
and compared between randomized treatment arms.
Subdistribution of hazard ratios23 and stratified Gray’s test24
were provided. All prespecified efficacy comparisons were
based on stratified analyses at random assignment
(Gleason score: # 7 v . 7 and PSA: # 20 v . 20 ng/mL).
Exploratory Analysis
To assess whether the treatment effect of adding docetaxel
to ADT 1 RT on OS or the occurrence of an RT-induced
cancer differed within PSA subgroups (, 4, . 20 v 4-20
ng/mL), the interaction test for heterogeneity of treatment
effect across PSA subgroups was carried out. Adjustment
was made for age and established PC prognostic factors
(Gleason score, T-category, and percent positive biopsies)
at random assignment, and unadjusted and adjusted HRs
(aHRs) and 95% CI were reported. The reference group of
PSA 4-20 ng/mL was selected for the interaction test given
previous data12 reporting a. 2-fold increased risk of PCSM
amongmen treated with ADT1RT for high-grade PC and a
PSA , 4 or . 20 ng/mL compared with 4-10 ng/mL,
whereas the PCSM risk was only slightly elevated among
men with a PSA of 10.1-20 ng/mL versus 4-10 ng/mL.
All statistical tests were two-sided, and statistical significance
was defined as a P value # .05, except for OS where the
stratified two-sided log-rank test , 0.048 was required for
statistical significance given the previous two interim ana-
lyses (Appendix 1). All analyses were performed using SAS
Software version 9.4 (SAS Institute Inc, Carey, NJ).
RESULTS
Patients
Patients were enrolled between September 21, 2005, and
January 13, 2015, from 18 centers (Appendix Table A1,
online only), and data were entered until June 29, 2020, at
which time the trial was stopped given that the number of
prespecified deaths needed for final analysis was observed
to have occurred. The intention-to-treat population in-
cluded 350 men, 175 in both randomized treatment arms.
As shown in Table 1, the patient clinical and demographic
characteristics were similar between the two treatment
arms. The median follow-up was 10.2 (interquartile range:
8.00-11.40 years) years.
Clinical Outcome Measures
Prespecified end points. The primary end point of OS was
analyzed after 89 deaths were observed (44 in the
ADT1 RT1 docetaxel arm and 45 in the ADT1 RT arm),
42 (47.19%) of which were from PC (22 in the
ADT1 RT1 docetaxel arm and 20 in the ADT1 RT arm).
Similar to a previous RCT,6 the OS curves initially diverged
favoring the docetaxel arm, but then merged with further
follow-up resulting in an HR (95% CI) comparing
ADT 1 RT 1 docetaxel with ADT 1 RT of 0.99 (0.65 to
1.51) and P 5 .98 with 10-year estimates (95% CI) of
survival of 72% (63 to 79) and 74% (66 to 80), respectively,
as shown in Figure 2A. Given the evidence of non-
proportionality, we evaluated RMST. The observed difference
in RMST over 10 years was 0.29 (95% CI, -0.19 to 0.76) year
(P5 .22): 9.11 years in the ADT1 RT1 docetaxel arm and
8.82 years in the ADT 1 RT arm. There was no evidence of
institutional heterogeneity between US and non-US sites in
the treatment effect of adding docetaxel to ADT1 RT on OS
(Pinteraction 5 .86).
Among men randomly assigned to receive docetaxel, sig-
nificantly less RT-induced cancers and related deaths (1 v
8 [4 were fatal]; age-adjusted HR, 0.13 [95% CI, 0.02 to
0.97]; P 5 .046) were observed as shown in Figure 2B.
Ten-year cumulative incidence estimates (95% CI) were
0.61% (0.06 to 3.09) versus 4.90% (2.13 to 9.40), re-
spectively, and the observed difference of 4.29% was
significant with a 95% CI that excluded 0.00 (0.51 to 8.07).
Figure 2C illustrates no significant difference in the cu-
mulative incidence of all other second cancers (HR, 0.89
[95% CI, 0.50 to 1.60]; P 5 .70), with 21 in the
ADT 1 RT 1 docetaxel arm and 24 in the ADT 1 RT arm.
4 © 2021 by American Society of Clinical Oncology
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TABLE 1. Demographic and Clinical Characteristics of 350 Study Patients Further Stratified by Randomized Treatment Arm
Demographic or Clinical Characteristic
Men Randomly Assigned
to ADT 1 RT (n 5 175)
Men Randomly Assigned
to
ADT 1 RT 1 Docetaxel
(n 5 175) All Men (N 5 350)
No. % No. % No. %
Race
Asian 3 1.71 1 0.57 4 1.11
Black or African American 4 2.29 5 2.86 9 2.57
Others 29 16.57 37 21.14 66 18.86
White 139 79.43 132 75.43 271 77.43
Ethnicity
Ethnicity not known 14 8.00 23 13.14 37 10.57
Hispanic or Latino 8 4.67 13 7.43 21 6.00
Non-Hispanic 153 87.43 139 79.43 292 83.43
2002 AJCC clinical T category at diagnosis per digital rectal examination
T1c 37 21.14 56 32.00 93 26.57
T2a 29 16.57 17 9.71 46 13.14
T2b 25 14.29 18 10.29 43 12.29
T2c 35 20.00 34 19.43 69 19.71
T3a 28 16.00 38 21.71 66 18.86
T3b 19 10.86 12 6.86 31 8.86
T4 2 1.14 0 0.00 2 0.57
Endorectal coil magnetic resonance imaging evidence of seminal vesicle invasion
Unknown 92 52.57 92 52.57 184 52.57
No 69 39.43 62 35.43 131 37.43
Yes 14 8.00 21 12.00 35 10.00
Biopsy Gleason score
3 1 3 4 2.29 5 2.86 9 2.57
3 1 4 33 18.86 39 22.29 72 20.57
3 1 5 1 0.57 3 1.71 4 1.14
4 1 3 53 30.29 49 28.00 102 29.14
4 1 4 19 10.85 16 9.14 35 10.00
4 1 5 45 25.71 42 24.00 87 24.86
5 1 3 2 1.14 1 0.57 3 0.86
5 1 4 12 6.86 14 8.00 26 7.43
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TABLE 1. Demographic and Clinical Characteristics of 350 Study Patients Further Stratified by Randomized Treatment Arm (continued)
Demographic or Clinical Characteristic
Men Randomly Assigned
to ADT 1 RT (n 5 175)
Men Randomly Assigned
to
ADT 1 RT 1 Docetaxel
(n 5 175) All Men (N 5 350)
No. % No. % No. %
5 1 5 6 3.43 6 3.43 12 3.43
Testosterone at ADT initiation , lower limit of normal
No 127 72.57 128 73.14 255 72.86
Yes 37 21.14 35 20.00 72 20.57
Unknown 11 6.29 12 6.86 23 6.57
ECOG performance status
0 162 92.57 168 96.00 330 94.28
1 13 7.43 7 4.00 20 5.71
Adult Comorbidity Score-2719
None 44 25.14 48 27.43 92 26.29
Minimal 89 50.86 74 42.29 163 46.57
Moderate 29 16.57 36 20.57 65 18.57
Severe 3 1.71 2 1.14 5 1.43
Unknown 10 5.71 15 8.57 25 7.14
PSA level in ng/mL at random assignment
# 20 130 74.29 126 72.00 256 73.14
. 20 45 25.71 49 28.00 94 26.86
Median Range Median Range Median Range
Age at random assignment, years 66 49-85 66 43-86 66 43-86
Percent positive biopsies (n 5 348)a 58 8-100 62.50 8-100 62 8-100
Abbreviations: ADT, androgen deprivation therapy; AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; RT, radiation therapy; T,
tumor.
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The secondary end point results are shown in Appendix 1
along with forest plots for the prespecified subgroup ana-
lyses for OS (Appendix Fig A1A, online only) and PCSM
(Appendix Fig A1B, online only).
Exploratory Analysis
As shown in Table 2, for men with a PSA, 4 ng/mL versus
4-20 ng/mL, the treatment effect of adding docetaxel to
ADT1 RT on OS differed (HR, 0.33, 1.40; Pinteraction 5 .09
and aHR, 0.27, 1.51; Pinteraction , .05, respectively) be-
cause of a lower PCSM in the docetaxel arm (0 of 13
[0.00%] v 4 of 14 [28.57%]) among men with PSA , 4
ng/mL (Table 3).
Amongmen with a PSA. 20 ng/mL versus 4-20 ng/mL, the
treatment effect of adding docetaxel to ADT 1 RT on OS
also differed (HR, 0.62, 1.40; Pinteraction 5 .08 and aHR,
0.60, 1.51; Pinteraction , .05 respectively). However, this
difference could not be explained by a decrease in PCSM
(Table 3) given that this rate was higher in the docetaxel
arm ([10 of 49] 20.41% v [8 of 45] 17.78%). Analogous
heterogenous treatment effects across PSA subgroups
were also noted for the composite end point of OS or the
occurrence of an RT-induced cancer (Table 2).
Safety
Both acute and late adverse events were analyzed in the 345
men who underwent protocol treatment (171 in the
ADT1 RT1 docetaxel arm and 174 in the ADT1 RT arm).
Discontinuation of treatment because of toxicity occurred in 7
(4.09%) men in the ADT 1 RT 1 docetaxel arm and 8
(4.60%) men in the ADT 1 RT arm. Adverse acute events
were reported by 26.90% of men randomly assigned to
ADT1RT1 docetaxel versus 10.34% in the ADT1RT arm.
Most were grade 2 or 3 (18.13% in the ADT 1 RT
1 docetaxel arm and 8.05% in the ADT 1 RT arm). These
respective estimates for grade 4 adverse events were 8.77%
and 1.72%. There was 1 (0.57%) grade 5 adverse event
(sudden death) in the ADT1RT arm that was not believed to
be treatment-related.
Adverse late events were reported by 81.87% of men in the
ADT 1 RT 1 docetaxel arm and 73.56% in the ADT 1 RT
arm. Most were grade 1 or 2 (67.25% in the ADT
B
175 162 153 126 95 62 20ADT + RT + docetaxel
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FIG 2. (A) Kaplan-Meier estimates of OS, (B) cumulative incidence estimates of RT-induced second cancers,a and (C) all other second cancers.a
aWithout age adjustment and includes four bladder, three rectal, one colon (had pelvic lymph node radiation), and one prostate second cancer.
ADT, androgen deprivation therapy; OS, overall survival; RT, radiation therapy.
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1 RT1 docetaxel arm and 63.22% in the ADT1 RT arm).
These respective estimates for grade 3 or 4 adverse events
were 14.62% and 10.34%.
DISCUSSION
Like previous RCTs,5-9 men with unfavorable-risk M0 PC
randomly assigned to receive ADT 1 RT 1 docetaxel
compared with ADT 1 RT did not experience prolonged
OS; however, neoadjuvant or concurrent docetaxel use in
the current study resulted in a significant reduction in the
incidence of RT-induced cancers. The ability to signifi-
cantly reduce RT-induced cancer incidence is clinically
relevant given that these cancers are typically radiation-
and chemotherapy-resistant25 and, as a result, often fatal as
observed in this study. Moreover, the recent report of an oral
formulation of docetaxel,26 which has amuchmore favorable
toxicity profile than intravenous (IV) docetaxel, provides the
opportunity to study oral docetaxel use to reduce the risk of
RT-induced cancer with minimal patient impact and across
a wide variety of cancers where RT and docetaxel use is part
of the management approach. In addition, we observed that
the treatment effect of adding docetaxel to ADT1 RT on OS
differed in men with a PSA , 4 ng/mL versus 4-20 ng/mL
because of the absence of PCSM in the docetaxel arm
among men with PSA , 4 ng/mL, providing evidence to
support the presence of a distinct biology in low PSA-
producing, unfavorable-risk PC that is docetaxel-sensitive.
Therefore, although docetaxel is not recommended when
managing men with unfavorable-risk PC given the incon-
clusive results from previous randomized trials,5-10 a sub-
group may benefit.
TABLE 2. Treatment Effect of Adding Docetaxel to ADT1RT onOS and on the Composite End Point of OS or the Occurrence of an RT-Induced CancerWithin
PSA-Defined Subgroups
PSA Subgroup

















27 8 0.33 (0.07 to 1.61) .09 9 0.27 (0.06 to 1.28) .06
0.27 (0.05 to 1.34) .05* 0.22 (0.05 to 1.08) .03
PSA 4-20
ng/mL
229 50 1.40 (0.80 to 2.45) Reference 53 1.33 (0.77 to 2.28) Reference
1.51 (0.86 to 2.67) 1.41 (0.82 to 2.43)
PSA . 20
ng/mL
94 31 0.62 (0.30 to 1.26) .08 31 0.61 (0.30 to 1.25) .09
0.60 (0.29 to 1.23) .05** 0.61 (0.30 to 1.23) .07
Abbreviations: ADT, androgen deprivation therapy; aHR, adjusted hazard ratio (348 patients; two men were missing percent positive biopsies); AJCC,
American Joint Committee on Cancer; HR, hazard ratio (350 patients); OS, overall survival; PSA, prostate-specific antigen; RT, radiation therapy.
*P 5 .047.
**P 5 .048.
aAdjustment for age and percent biopsies as continuous covariates and Gleason score (8-10 v 7 or less) and 2002 AJCC tumor category (T3,4 v T1,2) as
categorical covariates.
bInteraction test assessed whether the treatment effect of adding docetaxel to ADT1RT on OS and also on OS or RT-induced cancer differed betweenmen
with a PSA , 4 ng/mL or . 20 ng/mL versus a PSA of 4-20 ng/mL.
TABLE 3. Distribution of the Causes of Death by Randomized Treatment Arm for All Men andMenWith PSA Levels, 4 ng/mL, 4-20 ng/mL, and. 20 ng/mL
at Registration
PSA Subgroup < 4 ng/mL 4-20 ng/mL > 20 ng/mL All
Randomized
Treatment Arm ADT 1 RT ADT 1 RT 1 Docetaxel ADT 1 RT ADT 1 RT 1 Docetaxel ADT 1 RT ADT 1 RT 1 Docetaxel ADT 1 RT ADT 1 RT1 Docetaxel
Total No. of patients 14 13 116 113 45 49 175 175
Total No. of deaths 6 2 22 28 17 14 45 44
Cause of death, No. (%)
Prostate cancer 4 (28.57) 0 (0.00) 8 (6.90) 12 (10.62) 8 (17.78) 10 (20.41) 20 (11.43) 22 (12.57)
RT-induced
second cancer
0 (0.00) 0 (0.00) 2 (1.72) 0 (0.00) 2 (4.44) 0 (0.00) 4 (2.29) 0 (0.00)
All other second
cancers
0 (0.00) 0 (0.00) 4 (3.45) 4 (3.54) 2 (4.44) 2 (4.08) 6 (3.42) 6 (3.42)
Cardiovascular 1 (7.14) 1 (7.69) 4 (3.45) 4 (3.54) 3 (6.66) 1 (2.04) 8 (4.56) 6 (3.42)
Others 1 (7.14) 1 (7.69) 4 (3.45) 8 (7.08) 2 (4.44) 1 (2.04) 7 (4.00) 10 (5.71)
Abbreviations: ADT, androgen deprivation therapy; PSA, prostate-specific antigen; RT, radiation therapy.
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Several points require further discussion. First, docetaxel
has been FDA-approved for treatment27 of locally advanced
non–small-cell lung, gastric, head and neck, and breast
cancer and in the postoperative setting for node-positive
breast cancer and metastatic PC. Yet, the observation of
reduced RT-induced cancer incidence with docetaxel use
has not been previously reported. This can be explained by
the short life expectancy of patients because of the ad-
vanced stage of some of these cancers relative to the time to
onset of an RT-induced cancer and/or the lack of RT use in
the studies27 that led to FDA approval of docetaxel. Also, an
RP control arm was not available to adjust for the incidence
of expected cancers28 that can arise in the bladder and/or
rectum that are juxtaposed to the radiation planning target
volume.20 This means that the point estimates of RT-
induced cancers we report could include those expected
cancers and, therefore, may overestimate the true inci-
dence of RT-induced cancers. However, given the random
assignment, the occurrence of expected cancers between
randomized treatment arms should be balanced and
cancel out when evaluating differences over time. There-
fore, the age-adjusted HR of RT-induced cancer we report
reflects a significant decrease in the true incidence of RT-
induced cancer among men randomly assigned to the
neoadjuvant and concurrent docetaxel arm. Of importance,
previous RT-based RCTs6-10 used adjuvant and not neo-
adjuvant and concurrent docetaxel. Therefore, comparing
the age-adjusted HR of RT-induced cancer observed in the
current RCT with the values calculated using data from
previous RCTs6-10 would inform whether the use of adjuvant
versus neoadjuvant and concurrent docetaxel affects RT-
induced cancer incidence in a similar manner.
Second, the ADT duration in this study was six and not 24-36
months as it was in previous RCTs.5-10 However, the obser-
vation that adding docetaxel to ADT1 RT may prolong OS in
men with a PSA , 4 ng/mL should not be affected by this
difference in ADT duration. Specifically, high-grade PCs that
are low or non-PSA producing often have a short-lived PSA
response to ADT suggesting ADT resistance,11-16 making any
duration of ADT unlikely to affect the risk of death. Never-
theless, whether docetaxel can prolong OS in men with a
PSA , 4 ng/mL is hypothesis-generating given that our pre-
randomization stratification for PSA level was defined at
20 ng/mL and not 4 ng/mL and that the 95%CI for the OS HR
comparing ADT1RT1 docetaxel with ADT1RT inmenwith
a PSA , 4 ng/mL included 1.00. However, this hypothesis is
strengthened by adjustment for age, known PC prognostic
factors, and the absence of PCSM among men who had a
PSA , 4 ng/mL and were randomly assigned to receive
docetaxel, which could be explored further using individual
patient data from previous RCTs5-10 in a meta-analysis.
In conclusion, adding docetaxel to ADT 1 RT did not
prolong OS in men with unfavorable-risk PC, but decreased
RT-induced cancer incidence, and may prolong OS in the
subgroup of men with a PSA, 4 ng/mL by reducing PCSM.
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APPENDIX 1
Additional Eligibility Requirements
Eligible patients needed to be at least 30 years old and have an Eastern
Cooperative Oncology Group performance status of 0 or 1 and ade-
quate hematologic (WBC . 3,000/mm3, platelet count . 105/mm3,
and hemoglobin. 8.0 g/dL) and organ function (creatinine, 2.0 mg/
dL; total bilirubin , upper limit of normal [except for Gilbert’s syn-
drome]; AST, ALT, and alkaline phosphatase meeting combined
constraints [described in the Protocol]; and peripheral neuropathy
, grade 1).
Interim Analyses
Two interim analyses of overall survival (OS) were performed according
to the initial design and overseen by an independent Data Safety
Monitoring Board. Early stopping criteria are based on O’Brien and
Fleming’s29 use function for efficacy and the repeated confidence
interval methodology for the futility monitoring, as described in the
Protocol. The first interim analysis was conducted for the June 2012
Data Safety Monitoring Board meeting when 18 deaths (18 of 53, 34%
information time under the original design) were observed. The second
interim analysis was conducted for the 2015 November meeting when
34 deaths (34 of 53, 64% information time under the original design)
were observed. Both efficacy and futility analysis were conducted at
the two planned interim analyses, and neither led to premature ter-
mination per prespecified criteria from the Protocol.
A Protocol amendment was made in February 2018, which increased
the event number to 86 deaths for the same hypothesized improve-
ment in OS under the one-sided a 5 .025 and 90% power. The
decision to amend the analysis plan was made without knowledge by
the study team of the blinded interim analyses. To maintain the overall
type I error of 0.05 (two-sided), after accounting for the interim
analyses on the basis of group sequential theory, a two-sided P value
from the stratified log-rank test, .048 would indicate that the primary
end point OS was significantly improved in the experimental arm.
Secondary End Points
Secondary end points included prostate cancer–specific mortality
(PCSM), metastasis-free survival (MFS), and prostate-specific antigen
recurrence-free survival (PSA RFS) and were compared between
randomized treatment arms. PCSM was defined similarly to OS, but
non-PC death was counted as competing risk under a competing risk
model. MFS was measured from the date of random assignment to the
date of the first evidence of recorded distant metastases or death from
any cause or was censored at the date of last disease assessment if free
from distant disease. PSA RFS was defined as the time from the date of
random assignment to the earliest date of PSA failure (nadir 1 2 ng/
mL), initiation of salvage therapy or death from any causes, or censored
at the date of last disease assessment for those alive and without PSA
failure.
To assess the consistency of the treatment effect on OS and PCSM, we
conducted prespecified subgroup analysis by (1) biopsy Gleason score
(# 7 v. 7), (2) baseline serum testosterone levels (low v normal), and
(3) comorbidity subgroups (no or minimal v moderate or severe)
defined using the Adult Comorbidity Evaluation-27 metric.19 Hazard
ratios (HRs) reported for subgroup analyses were unadjusted. The
results are shown in Appendix Figures A1A and A1B.
There was no advantage to adding docetaxel to androgen deprivation
therapy plus radiation therapy with respect to the end points of PCSM
(subdistribution HR, 1.15 [95% CI, 0.63 to 2.09]; P5 .65), MFS (HR,
1.07 [95% CI, 0.75 to 1.54]; P5 0.69), and PSA RFS (HR, 1.05 [95%
CI, 0.79 to 1.40]; P 5 0.72).
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TABLE A1. Accrual by Site
Treatment Center Patients (No.)
Beth Israel Deaconess Medical Center 10
BWH/DFCI 128
Boston VA Medical Center 6
Calvary Mater Newcastle Hospital 44
Cancer Center of North Carolina 1
Cape Cod Hospital 8
City of Hope Medical Center 1
Dunedin Hospital, New Zealand 7
Hartford Hospital 2
Massachusetts General Hospital 1
Memorial Hermann Southwest Hospital 5
Milford Regional Cancer Center (BWH/DFCI affiliate) 3
Norris Comprehensive Cancer Center—University of Southern California 25
Sir Charles Gairdner Hospital 55
South Shore Hospital (BWH/DFCI affiliate) 5




Abbreviations: BWH, Brigham and Women’s Hospital; DFCI, Dana Farber Cancer Institute.
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0.75 (0.45 to 1.26)
1.65 (0.69 to 3.92)
0.83 (0.48 to 1.42)
1.38 (0.70 to 2.74)
0.87 (0.53 to 1.44)
1.56 (0.65 to 3.72)
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FIG A1. (A) HR and 95% CI. (B) Subdistribution HR and 95% CI. ADT, androgen deprivation therapy; HR, hazard ratio; LLN, lower limit of normal; RT,
radiation therapy.
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